Among these trials, the ALCHEMIST-EGFR (NCT02193282), probably the largest effort to address the role of EGFR TKI in the adjuvant setting, is a phase three study evaluating the efficacy of adding erlotinib for 2 years vs. placebo in patients with fully resected EGFR mutant stage IB–IIIA NSCLC, with OS as a primary endpoint. Here, EGFR is linked to non-small cell lung carcinoma.